Test-Retest of (18)F-Fluoroazomycin Arabinoside ([18F]FAZA) PET-CT of Solid Tumors
Status:
Not yet recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This goal of this clinical research study is to learn the best time to have a PET-CT scan
after receiving (18)F-fluoroazomycin arabinoside ([18F]FAZA).
During certain types of scans (like PET-CT scans), an "imaging agent" is injected into your
bloodstream to help certain parts of your body be more clearly seen during the scan.
[18F]FAZA is a new imaging agent designed to show how much oxygen is in a tumor during a
PET-CT scan.